- $798.55m
- $547.30m
- 13
- 15
- 49
- 14
Annual cashflow statement for Replimune, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -80.9 | -118 | -174 | -216 | -247 |
| Depreciation | |||||
| Non-Cash Items | 17.1 | 29 | 31.3 | 25.2 | 30.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.66 | 4.71 | 12.5 | 2.44 | 21 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -61.4 | -82.2 | -128 | -185 | -192 |
| Capital Expenditures | -2.39 | -2.34 | -2.27 | -5.66 | -6.69 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -186 | 0.53 | -140 | 103 | -17.1 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -189 | -1.81 | -143 | 97.2 | -23.8 |
| Financing Cash Flow Items | -0.895 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 372 | 6.6 | 311 | 16.3 | 252 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 123 | -76.6 | 40.6 | -72.1 | 36.7 |